Senators Question Trump's FDA Nominee on Mifepristone Safety, Vaccine Meeting Cancellation

Dr. Marty Makary, President Trump's nominee to lead the FDA, faced intense questioning during his confirmation hearing on various health issues, particularly regarding the abortion pill mifepristone and the abrupt cancellation of a critical flu vaccine advisory committee meeting. Senators from both parties expressed concerns over the FDA's previous safety regulations on mifepristone and pressed Makary on his plans to ensure data-driven policy decisions. Additionally, Senator Patty Murray highlighted the FDA's unprecedented cancellation of its annual meeting to recommend flu vaccine strains amid the worst flu season in 15 years, raising alarms about the implications for public health. Makary stated he would review existing data and consult with FDA scientists but did not outline a specific policy agenda. The hearing reflected the ongoing political tensions surrounding reproductive health and vaccine safety as the FDA's role is scrutinized. Both supportive and critical lawmakers sought assurance that science would guide FDA decisions under Makary's leadership.